Industry: Pharmaceuticals (See others in industry)
Address:Date | FilingType | Incremental Cash | Link to Raw Filing | |||
---|---|---|---|---|---|---|
2025-05-14 | New | Yet to Sell | $0 | Equity Only | 06b | SEC link |
2025-02-11 | Amended | $417,380 | $417,380 | Equity Only | 06b | SEC link |
2023-10-11 | New | Yet to Sell | $0 | Equity Only | 06b | SEC link |
2023-01-26 | Amended | $1,490,435 | $402,742 | Equity Only | 06b | SEC link |
2022-01-14 | Amended | $1,087,693 | $459,806 | Equity Only | 06b | SEC link |
2021-02-01 | Amended | $627,887 | $364,118 | Equity Only | 06b | SEC link |
2020-01-31 | Amended | $263,769 | $263,769 | Equity Only | 06b | SEC link |
2019-02-27 | New | Yet to Sell | $0 | Equity Only | 06b | SEC link |
2017-11-17 | New | Yet to Sell | $0 | Equity Only | 06b | SEC link |
2016-11-16 | Amended | $887,000 | $687,000 | Equity Only | 06b | SEC link |
2016-02-29 | New | $200,000 | $200,000 | Equity Only | 06b | SEC link |
Name | Role |
---|---|
W. Kendall Brown | Director |
Walter Kendall Brown | Director |
Benjamin F Cravatt | Director |
Mark G. Currie | Director |
Nabil Elkouh | Director |
Michael J. Higgins | Director |
Eduardo J. Martinez | Executive |
Eric R Olson | Director |
James P. Pearson | Director, Executive |
Shaker Sadasivam | Director |
Anne M. Sullivan | Executive |